An observational study in Adult Congenital Heart Disease, Pulmonary Hypertension and Connective Tissue Disease, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 1 site in United States. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-17.
Sponsored by Children's Hospital Medical Center, Cincinnati · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Heart Defects, Congenital by Children's Hospital Medical Center, Cincinnati — 4 open to participants now, 5 under way, 1 of them phase 3. Heart Defects, Congenital · Children's Hospital Medical Center, Cincinnati.
Among the 14 studies in Heart Defects, Congenital by Children's Hospital Medical Center, Cincinnati, this one is the only one that started in 2021, is one of 7 observational ones, and was the 13th registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
Browse Heart Defects, Congenital studies →4 of the 14 studies in Heart Defects, Congenital by Children's Hospital Medical Center, Cincinnati are open now, in 2 countries. Recruiting first, the newest first:
Children's Hospital Medical Center, Cincinnati · Sites in United States, Australia
Ages 18+
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 1 days–31 days
Children's Hospital Medical Center, Cincinnati
Ages 2 mo–2 yrs
By country, each count listing its studies:
Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.
This study: 16 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 2
First in 2010; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 119 across 440 observational studies indexed under Heart Defects, Congenital.
Median enrollment 39 across the 7 interventional studies, 92 across the 7 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
Children's Hospital Medical Center, Cincinnati is the lead sponsor of 673 studies on the registry; 129 are open to participants now.
Of its 57 completed or terminated interventional studies of FDA-regulated products, 32 (56%) have results posted.
2 of the studies in Heart Defects, Congenital by Children's Hospital Medical Center, Cincinnati that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04216927Phase 3Children's Hospital Medical Center, CincinnatiNO During CPB in Neonates to Reduce Risk of AKI | 2027-06-30 |
| NCT06175104Children's Hospital Medical Center, CincinnatiHeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Heart Defects, Congenital by Children's Hospital Medical Center, Cincinnati, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A repository of biospecimens and detailed phenotypic information collected longitudinally from adults with congenital heart disease and related conditions, with an aim to facilitate future research on biologic mechanisms of underlying disease, compensation and deterioration; biologic correlates of patient experience and functional status; associations between clinical characteristics and various biomarkers; and predictors of clinical outcomes.
The goals of this protocol are to collect, maintain, and manage tissue specimens of various types for adults with congenital heart disease, adults with related disorders, and a set of control participants. Ultimately, we plan to approach all clinical encounters for adults (≥16 years-old) in the Heart Institute (HI) - and, in the future with additional review, the cardiology departments of additional participating sites.
We will collect extensive data on all enrolled participants, and also collect information directly from participants (e.g., via surveys about symptoms and lifestyle, patient-reported outcome metrics) at baseline and on an ongoing basis (e.g. sequential outpatient visits and procedure encounters).
Participants will include individuals aged 16 years or older who are suspected of having or diagnosed with congenital heart disease (CHD), other cardiovascular disease, pulmonary hypertension, connective tissue disease, or a genetic condition; healthy volunteers, and comparison participants without CHD but with a diagnosis of heart failure or pulmonary hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additionally, a cohort (Control group A) of control subjects will be enrolled, again ≥16 years-old, self-reported non-smokers without a known history of diabetes mellitus, myocardial infarction, stroke, heart failure, or chronic kidney disease. These controls will be either:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Successful establishment of biospecimen repository
Defined as the number and type of biospecimens collected and successfully linked with corresponding clinical and phenotypic data.
Time frame: Day 1
Longitudinal biospecimen availability
Number of participants with repeated biospecimen collections across multiple timepoints.
Time frame: Day 1
Event-based biospecimen collection completeness
Availability of biospecimens collected before, during, and after defined clinical interventions (e.g., surgery, exercise testing).
Time frame: Day 1
Data completeness of linked clinical phenotypes
Proportion of participants with complete longitudinal clinical, demographic, and phenotypic datasets suitable for research.
Time frame: Day 1
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2021 (actual). Primary completion is estimated for Jan 2050, 342 months after the start.
Of 178 non-industry observational studies under Heart Defects, Congenital, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 83. This study's planned 342 months is above that.
Counting every sponsor, half of 185 studies reached it within 44 months; a quarter within 17 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Children's Hospital Medical Center, Cincinnati →